Immunome (IMNM) Projected to Post Quarterly Earnings on Thursday

Immunome (NASDAQ:IMNM) is projected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Immunome to post earnings of ($0.72) per share and revenue of $3.16 million for the quarter.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The company had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Stock Down 14.7 %

IMNM stock opened at $6.95 on Wednesday. The stock has a market capitalization of $604.31 million, a PE ratio of -0.86 and a beta of 1.93. Immunome has a 52 week low of $6.94 and a 52 week high of $26.70. The firm has a 50 day moving average of $9.67 and a 200 day moving average of $11.44.

Insider Buying and Selling

In other Immunome news, Director Jean Jacques Bienaime purchased 7,000 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the transaction, the director now owns 23,615 shares of the company’s stock, valued at $193,879.15. The trade was a 42.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Clay B. Siegall acquired 150,000 shares of the business’s stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 169,300 shares of company stock valued at $1,323,536. 8.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on IMNM. Lifesci Capital initiated coverage on Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target for the company. Guggenheim reduced their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Finally, Stephens reaffirmed an “overweight” rating and issued a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $25.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.